Reserachers reveal a potential therapy which might be an alternative to the harmul effects of 'chemo brain'.
The researchers of a recent study found that participants with an RS of 11-25 had an invasive disease-free survival (IDFS) rate at five years of 92.6 percent with a median follow-up of 58 months.
